logo
更新:2019-03-14
(Asso.) Scientist
面议
上海  | 社招  | 招1人
已结束
职位详情

The job holder will be working within Cell
Panel Team, with broad assay knowledge and skills, covered from pre-clinical assay
development to preclinical studies.

Key job
responsibilities include:

·      Cell Culture: Maintain variety cancer cell lines with quality. Experience in primary immune cells (e.g. T cells,
dendritic cells, macrophages) is plus.

·   Perform oncology panel screening experiments under GLS standards, from raw data
recording/capture/analysis & QC/reporting, etc.

·        
Understand cellular signaling transduction and act as a technical specialist in pre-clinical
assay development, with the knowledge of trouble shooting; experiment design;
analyze & data interpretation. Experienced in Flow Cytometry or other
multiplex assays (e.g.), MSD, ELISA, etc.

Requirements

·         Bachelor 3+ years research experience or equivalent, in industry environment.

·        
3+ years of mammalian cell culture; 2+ yr of pre-clinical assays; 1+yr of
screening.

·        
Strong problem solving and scientific skills in cellular assays, data analysis and
interpretation.

·        
Experience in screening platforms, automation, and database enabled environment.

·        
Good oral and written communication skills in both English and Chinese.

·        
Can-do attitude and teamwork spirit.

工作地址
上海市浦东新区
点击查看地图
公司介绍
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.

The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.

       迪哲医药,于2017年10月独立运营,是一家研发驱动型生物医药企业,致力于全球创新药物(First-in-class/ Best-in-class)探索、研发以及商业化。

       迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心,设立于中国上海,是阿斯利康全球四个研发中心之一(另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡);是国际一流、高产出的创新药研发机构,拥有全球领先的转化医学和新药分子设计与筛选技术平台;在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。

工商信息
以下信息来自
企业类型
有限责任公司(中外合资)
经营状态
存续
行业类型
研究和试验发展
成立日期
2017年10月27日
注册地址
无锡市新吴区净慧东路汇融商务广场E楼(5号楼)4105室
统一社会信用代码
91320214MA1T6H5736
若用人单位提供虚假招聘信息,以担保或其他任何名义收取财物,扣押或以保管为名索要证件,都属于违法行为,应当提高警惕。
发布于